(S)-2-amino-3-phenyl-propionic acid cyclopentyl ester | 205180-02-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-amino-3-phenyl-propionic acid cyclopentyl ester
• 英文别名: L-phenyl alanine cyclopentyl ester；L-phenylalanine cyclopentyl ester；cyclopentyl L-phenylalaninate；Cyclopentyl (2S)-2-amino-3-phenylpropanoate
• CAS: 205180-02-5
• 化学式: C₁₄H₁₉NO₂
• mdl: MFCD13329536
• 分子量: 233.31
• InChiKey: GIYPQZJJERZOKW-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-2-amino-3-phenyl-propionic acid cyclopentyl ester 在 氨 、 calcium carbonate 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 4.08h， 生成 cyclopentyl N-{5-[4-chloro-3-(methylsulfonyl)phenyl]-4-methyl-1,3-thiazol-2-yl}-L-phenylalaninate
  参考文献：
  名称：

  WO2007/129048

  摘要：

  公开号：
• 作为产物：
  描述：

  L-Phe-cyclopentyl ester.TsOH salt 在 sodium carbonate 作用下， 以 水 、 乙酸乙酯 为溶剂， 以86%的产率得到(S)-2-amino-3-phenyl-propionic acid cyclopentyl ester
  参考文献：
  名称：

  WO2006/117570

  摘要：

  公开号：

文献信息

• Cytostatic agents
  申请人：British Biotech Pharmaceuticals, Ltd.

  公开号：US06462023B1

  公开（公告）日：2002-10-08

  The present invention provide compounds exemplified by 2(R or S)-[2R-(S-Hydroxy-hydroxycarbamoyl-methyl)-4-methyl-pentanoylamine]-2-phenyl-ethanoic acid cyclopentyl ester; 2(R or S)-(3S-Hydroxycarbamoyl-2R-isobutyl-hex-5-enoylamino)-2-phenylethanoic acid isopropyl ester; 2(R or S)-[2R-(S-Hydroxycarbamoyi-methoxy-methyl)-4-methyl-pentanoylamino]-3-phenylethanoic acid cyclopentyl ester; 2(R or S)-(3S-Hydroxycarbamoyl-2R-isobutyl-hex-5-enoylamino)-2-(4-methoxyphenyl)ethanoic acid cyclopentyl ester; 2(R or S)-(3S-Hydroxycarbamoyl-2R-isobutyl-hex-5-enoylamino)-2-(thien-2-yl)ethanoic acid cyclopentyl ester; and 2(R or S)-(3S-Hydroxycarbamoyl-2R-isobutyl-hex-5-enoylamino)-2-(thien-3-yl)ethanoic acid cyclopentyl ester are cytostatic agents. Methods of treating proliferative cell growth disorders as well a methods of inhibiting hyper-proliferative cells are also disclosed.

  本发明提供了一系列化合物，例如2(R或S)-[2R-(S-羟基羟基甲酰胺基)-4-甲基-戊酰胺基]-2-苯乙酸环戊酯；2(R或S)-(3S-羟基甲酰胺基-2R-异丁基-己-5-烯酰氨基)-2-苯乙酸异丙基酯；2(R或S)-[2R-(S-羟基甲酰胺甲氧基甲基)-4-甲基-戊酰胺基]-3-苯乙酸环戊酯；2(R或S)-(3S-羟基甲酰胺基-2R-异丁基-己-5-烯酰氨基)-2-(4-甲氧基苯基)乙酸环戊酯；2(R或S)-(3S-羟基甲酰胺基-2R-异丁基-己-5-烯酰氨基)-2-(噻吩-2-基)乙酸环戊酯；以及2(R或S)-(3S-羟基甲酰胺基-2R-异丁基-己-5-烯酰氨基)-2-(噻吩-3-基)乙酸环戊酯均为抗增殖剂。还公开了治疗增殖性细胞生长障碍的方法以及抑制高增殖细胞的方法。
• [EN] INHIBITORS OF HSP90<br/>[FR] INHIBITEURS D'HSP90
  申请人：CHROMA THERAPEUTICS LTD

  公开号：WO2010043865A1

  公开（公告）日：2010-04-22

  The invention provides a compound which is (a) a pyrrolopyrimidine derivative of formula (I) or a tautomer thereof, or (b) a pharmaceutically acceptable salt, N-oxide, hydrate or solvate thereof: Formula (I) wherein R1, R2, R3, R4 and W are as defined herein. The compounds are useful in the treatment of diseases mediated b HSP90 and also in the treatment of inflammation.

  该发明提供了一种化合物，该化合物是(a) 公式(I)的吡咯吡嘧啶衍生物或其互变异构体，或者(b) 该化合物的药用可接受的盐、N-氧化物、水合物或溶剂化合物：公式(I)其中R1、R2、R3、R4和W如本文所定义。这些化合物在治疗由HSP90介导的疾病以及治疗炎症方面是有用的。
• [EN] P38 MAP KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA MAP KINASE P38
  申请人：CHROMA THERAPEUTICS LTD

  公开号：WO2009060160A1

  公开（公告）日：2009-05-14

  Compounds of formula (I) are inhibitors of p38 MAP kinase, and are therefore of utility in the treatment of, inter alia, inflammatory conditions including rheumatoid arthritis and COPD: formula (I) wherein: G is -N= or -CH=; D is an optionally substituted divalent mono- or bi-cyclic aryl or heteroaryl radical having 5 - 13 ring members; R6 is hydrogen or optionally substituted C1-C3 alkyl; P represents hydrogen and U represents a radical of formula (IA); or U represents hydrogen and P represents a radical of formula -A-(CH2)z-X1-L1 -Y-NH-CHR1R2 wherein A represents an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5 - 13 ring members; z, Y, L1, and X1 are as defined in the specification; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; and R2 is the side chain of a natural or non-natural alpha amino acid.

  公式（I）的化合物是p38 MAP激酶的抑制剂，因此在治疗炎症性疾病包括类风湿性关节炎和COPD方面具有效用：公式（I）其中：G是-N =或-CH =; D是具有5-13个环成员的可选取代的二价单环或双环芳基或杂芳基基团; R6是氢或可选取代的C1-C3烷基; P代表氢，U代表公式（IA）的基团;或U代表氢，P代表公式-A-（CH2）z-X1-L1-Y-NH-CHR1R2的基团，其中A代表具有5-13个环成员的可选取代的二价单环或双环碳环或杂环基团; z，Y，L1和X1如规范中定义; R1是羧酸基（-COOH）或可由一个或多个细胞内酯酶酶水解为羧酸基的酯基;而R2是天然或非天然α氨基酸的侧链。
• N-formyl hydroxylamine derivatives as antibacterial agents
  申请人：British Biotech

  公开号：US06476067B1

  公开（公告）日：2002-11-05

  Compounds of formula (I) are in the preparation of antibacterial agents, wherein: R1 represents hydrogen, C1-C6 alkyl or C1-C6 alkyl substituted by one or more halogen atoms; R2 represents a group R10(X)n—(ALK)— wherein R10 represents hydrogen, a C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkynyl, cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by (C1-C6)alkyl, (C1-C6)alkoyy, hydroxy, mercapto, (C1-C6)alkylthio, amino, halo, trifluoromethyl, cyano, nitro, —COOH, —CONH2, —COORA, —NHCORA, —CONHRA, —NHRA, —NRARB, or —CONRARB wherein RA and RB are independently a (C1-C6)alkyl group, and ALK represents a straight or branched divalent C1-C6 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene radical, which may be interrupted by one or more non-adjacent —NH—, —O— or —S— linkages, X represents —NH—, —O— or —S—, and n is 0 or 1, R represents hydrogen or C1-C6 alkyl, R3 represents the characterising group or a natural or non-natural &agr; amino acid in which any functional groups may be protected; and R4 represents an ester or thioester group.

  式(I)的化合物用于制备抗菌剂，其中：R1代表氢，C1-C6烷基或C1-C6烷基上取代一个或多个卤素原子；R2代表一个基团R10（X）n—（ALK）—，其中R10代表氢，C1-C6烷基，C2-C6烯基，C1-C6炔基，环烷基，芳基或杂环基，任何一个可以未取代或取代为（C1-C6）烷基，（C1-C6）烷氧基，羟基，巯基，（C1-C6）烷基硫基，氨基，卤素，三氟甲基，氰基，硝基，—COOH，—CONH2，—COORA，—NHCORA，—CONHRA，—NHRA，—NRARB或—CONRARB，其中RA和RB分别为（C1-C6）烷基基团，ALK代表直链或支链二价的C1-C6烷基，C2-C6烯基或C2-C6炔基基团，可以由一个或多个非相邻的—NH—，—O—或—S—连接中断，X代表—NH—，—O—或—S—，n为0或1，R代表氢或C1-C6烷基，R3代表表征基团或一种天然或非天然的α-氨基酸，其中任何功能基团均可保护；R4代表酯或硫酯基团。
• ENZYME INHIBITORS
  申请人：Davidson Alan Hornsby

  公开号：US20140163042A1

  公开（公告）日：2014-06-12

  Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R 1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R 2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, —C(═O), —S(═O) 2 —, —C(═O)O—, —C(O)NR 3 —, —C(═S)—NR 3 , —C(═NH)NR 3 or —S(═O) 2 NR 3 — wherein R 3 is hydrogen or optionally substituted C 1 -C 6 alkyl; L 1 is a divalent radical of formula -(Alk 1 ) m (Q) n (Alk 2 ) p - wherein m, n and p are independently 0 or 1, Q is (i) an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5-13 ring members, or (ii), in the case where both m and p are 0, a divalent radical of formula —X 2 -Q 1 - or -Q 1 -X 2 — wherein X 2 is —O—, S— or NR A — wherein R A is hydrogen or optionally substituted C 1 -C 3 alkyl, and Q 1 is an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5-13 ring members, Alk 1 and Alk 2 independently represent optionally substituted divalent C 3 -C 7 cycloalkyl radicals, or optionally substituted straight or branched, C 1 -C 6 alkylene, C 2 -C 6 alkenylene, or C 2 -C 6 alkynylene radicals which may optionally contain or terminate in an ether (—O—), thioether (—S—) or amino (—NR A —) link wherein R A is hydrogen or optionally substituted C 1 -C 3 alkyl; X 1 represents a bond; —C(═O); or —S(═O) 2 —; —NR 4 C(═O)—, —C(═O)NR 4 —, —NR 4 C(═O)NR 5 —, —NR 4 S(═O) 2 —, or —S(═O) 2 NR 4 — wherein R 4 and R 5 are independently hydrogen or optionally substituted C 1 -C 6 alkyl; z is 0 or 1; A represents an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system wherein the radicals R 1 R 2 NH—Y-L 1 -X 1 -[CH 2 ] Z — and HONHCO-[LINKER]- are attached different ring atoms; and -[Linker]- represents a divalent linker radical linking a ring atom in A with the hydroxamic acid group CONIIOII, the length of the linker radical, from the terminal atom linked to the ring atom of A to the terminal atom linked to the hydroxamic acid group, is equivalent to that of an unbranched saturated hydrocarbon chain of from 3-10 carbon atoms.

  式(I)的化合物是组蛋白去乙酰化酶活性抑制剂，可用于治疗癌症等疾病，其中R1是羧酸基（-COOH）或可由一个或多个细胞内羧酸酯酶水解为羧酸基的酯基；R2是天然或非天然α氨基酸的侧链；Y是键，-C（=O），-S（=O）2-，-C（=O）O-，-C（=O）NR3-，-C（=S）-NR3，-C（=NH）NR3或-S（=O）2NR3-，其中R3是氢或可选取代的C1-C6烷基；L1是式-(Alk1)m(Q)n(Alk2)p-的二价基团，其中m、n和p独立地为0或1，Q是（i）一个可选取代的二价单环或双环碳环或杂环基团，具有5-13个环成员，或（ii）在m和p均为0的情况下，是式-Q1-X2-或-X2-Q1-的二价基团，其中X2是-O-，-S-或-NRA-，其中RA是氢或可选取代的C1-C3烷基，Q1是可选取代的二价单环或双环碳环或杂环基团，具有5-13个环成员，Alk1和Alk2独立地表示可选取代的二价C3-C7环烷基基团，或可选取代的直链或支链，C1-C6烷基，C2-C6烯基或C2-C6炔基基团，其可以可选地含有或终止于醚（-O-），硫醚（-S-）或氨基（-NRA-）链，其中RA是氢或可选取代的C1-C3烷基；X1表示键，-C（=O）或-S（=O）2-；-NR4C（=O）-，-C（=O）NR4-，-NR4C（=O）NR5-，-NR4S（=O）2-或-S（=O）2NR4-，其中R4和R5独立地为氢或可选取代的C1-C6烷基；z为0或1；A表示可选取代的单环、双环或三环碳环或杂环系统，其中基团R1R2NH-Y-L1-X1-[CH2]Z-和HONHCO-[LINKER]-附着在不同的环原子上；-[Linker]-表示将A中的一个环原子与羟酰胺酸基团CONIIOII连接的二价连接基团，连接基团的长度，从连接到A环原子的末端原子到连接到羟酸胺基团的末端原子，相当于从3-10个碳原子的直链饱和碳氢链的长度。